Development of a Novel Therapy for Ovarian Clear Cell Carcinoma via Functional Nanoparticles

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09513
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Shiga University of Medical Science
• Principal Investigator: Amano Tsukuru 滋賀医科大学, 医学部, 講師 (20613467)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 卵巣明細胞癌

Outline of Final Research Achievements

We have established a size control method for mesoporous silica nanoparticles, and have succeeded in achieving excellent solubility by modifying polyglycerol on the core particles with a diameter of about 50 nm. On the other hand, we found that retinol dehydrogenase 10 (RDH10), an enzyme that metabolizes vitamin A, is specifically expressed in ovarian clear cell carcinoma by immunostaining and Western blotting using a large number of clinical samples. Furthermore, we identified that RDH10 contributes significantly to intracytoplasmic glycogen storage in ovarian clear cell carcinoma via phosphoenolpyruvate carboxykinase, a glycosylation synthase, and is involved in the acquisition of stem cell potential and resistance of cancer cells to therapy.

Free Research Field

婦人科腫瘍学

Academic Significance and Societal Importance of the Research Achievements

化学療法抵抗性である卵巣明細胞癌に高発現し治療抵抗性に関与する新規分子（RDH10）を同定したことは今後の新規治療確立の土台となる成果であると考えられる。まさメソポーラスシリカナノ粒子のサイズをコントロールし可溶性を持たせる技術についても今後ドラッグデリバリーの分野で応用が期待できる。